IMDX — Insight Molecular Diagnostics Inc.

IMDX Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: Low levels of revenue expected for lab services in 2026, with almost no revenue anticipated in Q1 2026.
• Research and Development: Increased R&D expenses in Q4 due to software development and clinical trial costs related to FDA submission. Expected to decrease in Q1 2026.
• Cash Burn: Average cash burn projected at $7.5 million per quarter, with higher expenses in the first half of 2026 due to timing of payments and anticipated revenue growth in the latter half.
• Funding: Completed a $26 million offering to support commercialization and R&D efforts.

2. Strategic Updates and Business Highlights

• FDA Submission: Submitted GraftAssureDx for FDA review, marking a significant milestone as the first dd-cfDNA assay submitted for authorization.
• Registry Engagement: 28 centers engaged in the GALACTIC registry, with a goal of 50 centers to drive clinical adoption and data collection.
• Market Expansion: Plans to expand GraftAssure into heart transplant testing, leveraging existing technology designed to be organ-agnostic.
• Reimbursement Strategy: Medicare reimbursement rate for GraftAssure set at $27.53, with ongoing discussions for reimbursement in the UK and EU.

3. Forward Guidance and Outlook

• 2026 Goals: Focus on expanding market access, launching GraftAssure for research use, and increasing engagement with transplant centers.
• Market Opportunity: Total addressable market valued at over $2 billion, with expectations for growth driven by increased demand for dd-cfDNA testing in transplant management.
• Sales Pipeline: Engaged with 37 transplant centers, with an average expected revenue of $1 million per center annually.

4. Bad News, Challenges, or Points of Concern

• Revenue Challenges: Anticipated low revenue in the first half of 2026 raises concerns about cash flow sustainability.
• Competition and Adoption: Convincing clinicians to adopt GraftAssure over existing methods remains a challenge, with the need for robust head-to-head data to demonstrate efficacy.
• Regulatory Risks: Dependence on FDA approval and subsequent reimbursement processes introduces uncertainty in timelines and market entry.

5. Notable Q&A Insights

• Registry Participation: Participation in the registry is expected to be self-funding, with the goal of converting registry participants to in-house testing for profitability.
• Bio-Rad Agreement: A 90-day negotiation window for commercial rights post-FDA authorization is in place, with ongoing discussions already occurring.
• Heart vs. Liver Testing: The focus on heart transplant testing is driven by higher demand and urgency in testing compared to liver transplants, which have more treatment options.
• Billing and Coding: A new Z code for the regulated version of the test is being established to facilitate reimbursement, with a separate process for MACs outside of MolDx.

Overall, IMDX is positioned for growth with its innovative GraftAssure technology, but faces challenges in revenue generation and clinician adoption as it navigates the regulatory landscape.